Lorbrena for previously-treated ALK-positive metastatic non-small cell lung cancer, approved from FDA
The FDA ( U.S. Food and Drug Administration ) has approved Lorbrena ( Lorlatinib ),
a third-generation anaplastic lymphoma kinase ( ALK ) tyrosine kinase inhibitor ( TKI ) for patients with ALK-posit ...
read article